A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants
Part of paid clinical trials in Austin, Texas.
- Sponsor
- Agios Pharmaceuticals, Inc.
- Study ID
- NCT04696393
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy Volunteers
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 64 Years
- Healthy Volunteers
- Accepted
Interventions
- Mitapivat tablet — DRUGOral tablets
Study Details
The primary purpose of this study is to characterize and compare the pharmacokinetic profiles of mitapivat following a single dose administration of 100 mg mitapivat in two tablet formulations (50 mg and 100 mg tablet strengths) in healthy adult participants.
Key Dates
- Start date
- Jan 6, 2021
- Status verified
- Apr 2021
- Primary completion
- Mar 19, 2021
- Completion
- Mar 19, 2021
Study Design
- Enrollment
- 26 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment Sequence 1: ABParticipants will receive Treatment A (mitapivat 100 milligram \[mg\] tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
- Experimental: Treatment Sequence 1: BAParticipants will receive Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment A (mitapivat 100 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.
Primary Outcome Measure
Area Under the Plasma Concentration Versus Time Curve (AUC) of Mitapivat From Time 0 to the Last Quantifiable Concentration (AUC0-t) [ Time Frame: Pre-dose and multiple time points post-dose (up to 120 hours) ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| PPD Development, LP | Austin | Texas | 78744 | - |
Find similar trials in Austin, TX
By research site
Related Studies
- A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)PHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Glendale, California
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy VolunteersPHASE1 · Recruiting · Mannkind Corporation · San Antonio, Texas
- Blood Flow Restriction (BFR) Training on the Ulnar Collateral Ligament (UCL)Recruiting · The Methodist Hospital Research Institute · Houston, Texas
- Liberty Analyzer WBC System: Reference Interval StudyEnrolling By Invitation · Entia Ltd · College Station, Texas